Ezetimibe
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor used for hypercholesterolemia and mixed dyslipidemia. The TxGNN model predicts it may be effective for Hyperlipoproteinemia, with 50 clinical trials and 19 publications currently supporting this direction — though as detailed below, this is less a novel “repurposing” signal and more a confirmation of ezetimibe’s already-established lipid-lowering pharmacology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia / mixed dyslipidemia (based on established pharmacology; not verifiable against a SAHPRA-approved product text, as no license record exists in this evidence pack) |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available from DrugBank in this evidence pack (flagged as a High-severity data gap). Based on established pharmacological knowledge, ezetimibe is a selective cholesterol absorption inhibitor that blocks the intestinal NPC1L1 transporter, reducing delivery of dietary and biliary cholesterol to the liver and lowering LDL-C. It is used as monotherapy or in fixed-dose combination with statins (e.g., simvastatin, atorvastatin, rosuvastatin), and its efficacy in hypercholesterolemia and mixed dyslipidemia is well established through decades of clinical use.
Hyperlipoproteinemia is a broad diagnostic category encompassing elevated LDL-cholesterol and/or triglyceride-rich lipoproteins — mechanistically, this is essentially the same lipid pathway ezetimibe already targets in its approved use. As the underlying repurposing rationale notes, this is not a typical old-drug-new-use case: the evidence base consists largely of existing Phase 3/4 trials and post-marketing surveillance for ezetimibe’s core lipid-lowering activity, rather than trials in a mechanistically distinct disease.
The clinical trial record strongly supports this overlap: large placebo-controlled and active-comparator Phase 3/4 studies (e.g., ezetimibe/simvastatin plus fenofibrate, ezetimibe plus colesevelam, the ENHANCE trial) directly evaluate ezetimibe-based regimens in hyperlipidemic populations, reinforcing that the TxGNN signal reflects confirmatory rather than exploratory evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00093899 | Phase 3 | Completed | 611 | Ezetimibe/simvastatin + fenofibrate coadministration in mixed hyperlipidemia; cholesterol-lowering effects assessed |
| NCT00655265 | Phase 4 | Completed | 86 | Colesevelam as add-on to statin + ezetimibe in familial hypercholesterolaemia not at LDL-C target |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in HeFH |
| NCT06005597 | Phase 3 | Completed | 407 | Obicetrapib/ezetimibe fixed-dose combination on top of maximally tolerated therapy in HeFH/ASCVD |
| NCT00092560 | Phase 3 | Completed | 587 | Fenofibrate + ezetimibe coadministration efficacy/safety in mixed hyperlipidemia |
| NCT00092573 | Phase 3 | Completed | 576 | Fenofibrate + ezetimibe coadministration, safety and effectiveness in mixed hyperlipidemia |
| NCT00271817 | Phase 3 | Completed | 1220 | Ezetimibe/simvastatin + extended-release niacin in Type IIa/IIb hyperlipidemia |
| NCT00704444 | N/A | Completed | 11332 | Large Japanese post-marketing use investigation of Zetia (ezetimibe) mono/combination therapy, 12-week safety/efficacy |
| NCT04929249 | Phase 3 | Completed | 450 | VICTORION-INITIATE: “inclisiran first” strategy vs usual care (including ezetimibe) on LDL-C in ASCVD |
| NCT00652431 | Phase 1 | Completed | 18 | PK/drug-interaction study: Vytorin (ezetimibe/simvastatin) with Niaspan (extended-release niacin) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM trial: fixed-dose obicetrapib + ezetimibe significantly reduces LDL-C |
| 25282519 | 2015 | RCT | Lancet | RUTHERFORD-2: evolocumab vs placebo in HeFH, with statin ± ezetimibe background therapy |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide in HeFH patients not at LDL-C goal on existing therapy |
| 29219151 | 2017 | Review | Nature Reviews Disease Primers | Comprehensive review of familial hypercholesterolaemia pathophysiology and treatment |
| 37762244 | 2023 | Review | Int J Mol Sci | Pathophysiology, diagnosis, and treatment of postprandial hyperlipidemia |
| 40682836 | 2025 | Review | Molecular Medicine Reports | Research advances in current drugs targeting hyperlipidemia |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | Comprehensive review of PCSK9 inhibitors as adjuncts to statin/ezetimibe therapy |
| 23956253 | 2013 | Consensus Statement | European Heart Journal | EAS consensus: FH is underdiagnosed/undertreated, guidance for CHD prevention |
| 33766264 | 2021 | Review | J Am Coll Cardiol | New and emerging LDL-C/ApoB-lowering therapies, positioning ezetimibe among treatment options |
| 25053660 | 2014 | Consensus Statement | European Heart Journal | EAS position paper on homozygous FH detection and clinical management |
South Africa Market Information
Ezetimibe currently has no active SAHPRA product registrations on file in this evidence pack (0 licenses), and the drug’s market status is recorded as not marketed in South Africa. No product-level details (registration number, product name, dosage form, approved indication text) are available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: retrieval of the PI/warnings and contraindications is flagged as a Blocking data gap in this evidence pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication is backed by an L1 evidence level (multiple completed Phase 3/4 RCTs), but this largely reflects ezetimibe’s already-established lipid-lowering pharmacology rather than a genuinely novel indication. Two critical gaps prevent a stronger “Go” recommendation: the drug is not currently marketed in South Africa (0 SAHPRA registrations), and the SAHPRA-approved warnings/contraindications data needed for the safety screen (S1) is missing — a Blocking-severity gap.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI): warnings, precautions, and contraindications (Blocking)
- DrugBank/MOA detail to formally substantiate the mechanistic link (High priority)
- Confirmation of South African market-entry pathway, since there are currently no active registrations
- Clarification of whether “hyperlipoproteinemia” represents a distinct label extension or falls within ezetimibe’s existing approved indications elsewhere
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.